State Street’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-697,201
| Closed | -$10.4M | – | 3660 |
|
|
2016
Q2 | $10.4M | Sell |
697,201
-111,765
| -14% | -$1.44M | ﹤0.01% | 2201 |
|
|
2016
Q1 | $9.85M | Buy |
808,966
+112,644
| +16% | +$1.58M | ﹤0.01% | 2185 |
|
|
2015
Q4 | $11.1M | Sell |
696,322
-633,909
| -48% | -$9.98M | ﹤0.01% | 2124 |
|
|
2015
Q3 | $20.4M | Buy |
1,330,231
+167,438
| +14% | +$3.62M | ﹤0.01% | 1726 |
|
|
2015
Q2 | $28.3M | Buy |
1,162,793
+106,566
| +10% | +$2.55M | ﹤0.01% | 1631 |
|
|
2015
Q1 | $24.6M | Buy |
1,056,227
+121,120
| +13% | +$3.21M | ﹤0.01% | 1705 |
|
|
2014
Q4 | $23.5M | Buy |
935,107
+189,607
| +25% | +$5.56M | ﹤0.01% | 1683 |
|
|
2014
Q3 | $23.2M | Sell |
745,500
-13,283
| -2% | -$360K | ﹤0.01% | 1630 |
|
|
2014
Q2 | $19.6M | Buy |
758,783
+5,106
| +0.7% | +$113K | ﹤0.01% | 1817 |
|
|
2014
Q1 | $17.6M | Buy |
753,677
+460,787
| +157% | +$10.1M | ﹤0.01% | 1878 |
|
|
2013
Q4 | $7.43M | Buy |
292,890
+48,291
| +20% | +$1.09M | ﹤0.01% | 2348 |
|
|
2013
Q3 | $4.99M | Buy |
244,599
+78,709
| +47% | +$1.75M | ﹤0.01% | 2533 |
|
|
2013
Q2 | $3.48M | Buy |
+165,890
| New | +$2.96M | ﹤0.01% | 2667 |
|
State Street's SGNT Position: Q3 2016 in Review
State Street sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 697,201 shares — an estimated $10.4M sold.
State Street first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $28.3M in Q2 2015. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- State Street reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- State Street sold 697,201 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $10.4M.
- State Street first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- State Street's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $28.3M in Q2 2015.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on State Street's 13F filing for Q3 2016, filed 14 Nov 2016.